This site is intended for US audiences only.

Skip to content

Main Navigation

For Patients
For Healthcare Professionals
Resources

Ficlatuzumab

Posted on November 30, 2023 by lum-dev

(also known by its research code AV-299): A potent humanized IgG1 monoclonal antibody that targets hepatocyte growth factor, or HGF.

Post navigation

CarcinomaHead and neck cancer

Ficlatuzumab is an investigational drug and has not yet been approved by the US Food and Drug Administration (FDA).

Footer Navigation

Terms of Use
Privacy Policy
Cookie Policy
Contact Us

© 2024 AVEO Pharmaceuticals, Inc. All rights reserved. US-MAT-00305 4/24